Marvel Biosciences says MB-204 improves autism-like behaviors in Shank3 mouse study

• Marvel Biosciences reported preliminary preclinical results for MB-204 in a Shank3 mouse model linked to Phelan-McDermid syndrome.
• Findings were already presented as early results; final statistical analysis remains pending.
• MB-204 improved a broad range of autism-related behaviors, with performance generally matching or beating istradefylline in head-to-head testing.
• Management framed the cross-model readthrough as supporting a potentially broader autism opportunity ahead of human clinical development.
• Researchers said the full dataset is expected to be presented at upcoming conferences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marvel Biosciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080645PRIMZONEFULLFEED9841881) on October 08, 2026, and is solely responsible for the information contained therein.